Drug-Related Pneumonitis in Patients Receiving Vedolizumab Therapy for Inflammatory Bowel Disease

Daniela Pugliese; Giuseppe Privitera; Tommaso Schepis; Luigi Larosa; Sara Onali; Sebastiano Onali; Franco Scaldaferri; Antonio Gasbarrini; Flavio Caprioli; Francesca Caprioli; Alessandro Armuzzi

doi:10.1016/j.cgh.2021.08.041

Drug-Related Pneumonitis in Patients Receiving Vedolizumab Therapy for Inflammatory Bowel Disease

Daniela Pugliese
, Giuseppe Privitera
, Tommaso Schepis
, Luigi Larosa
, Sara Onali
, Sebastiano Onali
, Franco Scaldaferri
, Antonio Gasbarrini
, Flavio Caprioli
, Francesca Caprioli
, Alessandro Armuzzi

University of Cagliari
IRCCS Fondazione Istituto Nazionale per lo studio e la cura dei tumori - Milano

Research output: Contribution to journal › Article

Abstract

Noninfective drug-related pneumonitis (DRP) is a well-known adverse effect of several drugs: clinical manifestations have mostly an acute/subacute onset and vary from mild to life-threatening. Several DRP cases have been described in patients receiving anti-tumor necrosis factor α, rituximab, and tocilizumab.1,2 To date, only 4 reports of vedolizumab-related pneumonitis have been presented.3-5.

Original language	English
Pages (from-to)	e1483-e1487
Journal	Clinical Gastroenterology and Hepatology
Volume	20
DOIs	https://doi.org/10.1016/j.cgh.2021.08.041
Publication status	Published - 2022

Keywords

INFLAMMATORY BOWEL DISEASE
VEDOLIZUMAB

Access to Document

10.1016/j.cgh.2021.08.041

Cite this

@article{d9c589d7b3e049d4b82516e85d24d130,

title = "Drug-Related Pneumonitis in Patients Receiving Vedolizumab Therapy for Inflammatory Bowel Disease",

abstract = "Noninfective drug-related pneumonitis (DRP) is a well-known adverse effect of several drugs: clinical manifestations have mostly an acute/subacute onset and vary from mild to life-threatening. Several DRP cases have been described in patients receiving anti-tumor necrosis factor α, rituximab, and tocilizumab.1,2 To date, only 4 reports of vedolizumab-related pneumonitis have been presented.3-5.",

keywords = "INFLAMMATORY BOWEL DISEASE, VEDOLIZUMAB, INFLAMMATORY BOWEL DISEASE, VEDOLIZUMAB",

author = "Daniela Pugliese and Giuseppe Privitera and Tommaso Schepis and Luigi Larosa and Sara Onali and Sebastiano Onali and Franco Scaldaferri and Antonio Gasbarrini and Flavio Caprioli and Francesca Caprioli and Alessandro Armuzzi",

year = "2022",

doi = "10.1016/j.cgh.2021.08.041",

language = "English",

volume = "20",

pages = "e1483--e1487",

journal = "Clinical Gastroenterology and Hepatology",

issn = "1542-3565",

publisher = "W.B. Saunders",

}

TY - JOUR

T1 - Drug-Related Pneumonitis in Patients Receiving Vedolizumab Therapy for Inflammatory Bowel Disease

AU - Pugliese, Daniela

AU - Privitera, Giuseppe

AU - Schepis, Tommaso

AU - Larosa, Luigi

AU - Onali, Sara

AU - Onali, Sebastiano

AU - Scaldaferri, Franco

AU - Gasbarrini, Antonio

AU - Caprioli, Flavio

AU - Caprioli, Francesca

AU - Armuzzi, Alessandro

PY - 2022

Y1 - 2022

N2 - Noninfective drug-related pneumonitis (DRP) is a well-known adverse effect of several drugs: clinical manifestations have mostly an acute/subacute onset and vary from mild to life-threatening. Several DRP cases have been described in patients receiving anti-tumor necrosis factor α, rituximab, and tocilizumab.1,2 To date, only 4 reports of vedolizumab-related pneumonitis have been presented.3-5.

AB - Noninfective drug-related pneumonitis (DRP) is a well-known adverse effect of several drugs: clinical manifestations have mostly an acute/subacute onset and vary from mild to life-threatening. Several DRP cases have been described in patients receiving anti-tumor necrosis factor α, rituximab, and tocilizumab.1,2 To date, only 4 reports of vedolizumab-related pneumonitis have been presented.3-5.

KW - INFLAMMATORY BOWEL DISEASE

KW - VEDOLIZUMAB

KW - INFLAMMATORY BOWEL DISEASE

KW - VEDOLIZUMAB

UR - http://hdl.handle.net/10807/204153

U2 - 10.1016/j.cgh.2021.08.041

DO - 10.1016/j.cgh.2021.08.041

M3 - Article

SN - 1542-3565

VL - 20

SP - e1483-e1487

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

ER -

Drug-Related Pneumonitis in Patients Receiving Vedolizumab Therapy for Inflammatory Bowel Disease

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this